Breaking News Instant updates and real-time market news.

IMMU

Immunomedics

$3.36

-0.11 (-3.17%)

09:03
11/29/16
11/29
09:03
11/29/16
09:03

venBio responds to Immunomedics' postponement of annual meeting

venBio Select Advisor, the beneficial owner of approximately 9.5 million shares, or 9.0%, of Immunomedics, Inc. and its largest stockholder, issued the following statement regarding the company's sudden announcement that it will postpone its Annual Meeting, which was originally scheduled for December 14, 2016, to February 16, 2017: "Immunomedics' decision to postpone its Annual Meeting does a severe disservice to the Company's stockholders. We believe investors deserve the opportunity to voice, without delay, their frustration at the strategic missteps of the Company's leadership. By denying stockholders their right to elect directors this year, we believe the Company is simply perpetuating the pattern of self-serving actions and value destruction that have characterized Immunomedics to date. Further, we note that Immunomedics' delay of the meeting is a clear violation of Delaware corporate law, as the new meeting would be more than the permissible 13 month period since the prior meeting on December 2, 2015. As such, we are considering all options for protecting stockholders' rights under applicable law. Importantly, we are also concerned that management, in their push to show 'progress', could make rash decisions that will prove detrimental to the Company and to all stockholders. 'Fast-tracking' any purported deal or partnership to show "progress", would raise the question of whether this board really cares more about what is best for the value and future of the Company or preserving their own positions. The only thing that has changed ahead of the Company's attempts to outline its strategy going forward has been our public involvement. We believe that this speaks to the fact that the Company felt no need to make progress on these fronts until feeling the brunt of public pressure. In our view, Immunomedics is merely paying lip service to the concerns of its investor base, and lacks the ability and willingness to effect meaningful change. We of course appreciate the Company saying that they are open to engagement with us, and remain receptive to any ideas they put forth. However, we continue to believe that Immunomedics must truly commit to transformative change that is in the best interests of all stockholders. Furthermore, the Company's excuse that it is delaying the meeting to give stockholders the opportunity to evaluate the Company's progress is absurd. Stockholders have already had a full year to evaluate progress since the last annual meeting and should be allowed to exercise their right to vote without delay. The incumbent Board should not prioritize its desire to stay in office over the rights of its stockholders. At this point, Immunomedics has had ample time to make meaningful changes that would set the Company on the path towards success. It is time to choose the path of experience, competence and value creation, rather than the path of stagnation, management self-enrichment and shareholder value destruction. We urge all stockholders to vote FOR all four of our Nominees on the GOLD proxy card as soon as it becomes available."

  • 03

    Dec

  • 14

    Dec

  • 16

    Feb

IMMU Immunomedics
$3.36

-0.11 (-3.17%)

05/06/16
JEFF
05/06/16
UPGRADE
Target $5
JEFF
Buy
Immunomedics upgraded to Buy from Hold at Jefferies
Jefferies analyst Chris Howerton upgraded Immunomedics to Buy saying IMMU-132 continues to demonstrate impressive clinical data in solid tumors. The analyst sees a greater likelihood of Immunomedics securing a partner for the asset following recent data. He raised his price target for the shares to $5.00 from $1.50.
06/21/16
WELS
06/21/16
DOWNGRADE
WELS
Market Perform
Immunomedics downgraded to Market Perform from Outperform at Wells Fargo
10/06/16
JEFF
10/06/16
INITIATION
Target $5.5
JEFF
Buy
Immunomedics assumed with a Buy at Jefferies
Jefferies analyst Matthew Andrews assumed coverage of Immunomedics with a Buy rating and raised his price target for the shares to $5.50 from $5. IMMU-132's "promising results" in Triple Negative breast cancer sets the stage for a partnership deal in the coming months, Andrews tells investors in a research note.
10/18/16
JEFF
10/18/16
NO CHANGE
JEFF
Jefferies sees 'attractive buying opportunities' in Biotech
The Jefferies Biotechnology team sees "attractive buying opportunities" amidst the pre-election weakness. While volatility will likely continue into the election, valuation multiples are near-historic lows and policy concerns, while valid, are likely overstated, the analysts tell investors in a research note. They recommend using the weakness to buy select names ahead of a potential improvement in sentiment. Jefferies likes Gilead (GILD) and Celgene (CELG) among large-caps, The Medicines Co. (MDCO), Alkermes (ALKS) and Vertex (VRTX) among mid-caps, and Alder Biopharmaceuticals (ALDR), Cempra (CEMP), Ultragenyx (RARE) and Immunomedics (IMMU) among small-caps.

TODAY'S FREE FLY STORIES

TIF

Tiffany

$92.31

0.52 (0.57%)

06:38
06/27/17
06/27
06:38
06/27/17
06:38
Recommendations
Tiffany analyst commentary  »

Tiffany added to US 1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$32.50

0.77 (2.43%)

06:36
06/27/17
06/27
06:36
06/27/17
06:36
Hot Stocks
Micron exploring sale of discontinued Lexar business »

Micron Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 29

    Aug

MON

Monsanto

$117.80

0.78 (0.67%)

06:33
06/27/17
06/27
06:33
06/27/17
06:33
Downgrade
Monsanto rating change  »

Monsanto downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

FMSA

Fairmount Santrol

$3.68

-0.05 (-1.34%)

06:32
06/27/17
06/27
06:32
06/27/17
06:32
Downgrade
Fairmount Santrol rating change  »

Fairmount Santrol…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGO

Assured Guaranty

$41.55

0.9 (2.21%)

06:32
06/27/17
06/27
06:32
06/27/17
06:32
Hot Stocks
S&P affirms Assured Guaranty's AA financial strength ratings with stable outlook »

Assured Guaranty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FET

Forum Energy

06:32
06/27/17
06/27
06:32
06/27/17
06:32
Downgrade
Forum Energy rating change  »

Forum Energy downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLB

Schlumberger

$65.89

-0.04 (-0.06%)

06:32
06/27/17
06/27
06:32
06/27/17
06:32
Downgrade
Schlumberger rating change  »

Schlumberger downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

HP

Helmerich & Payne

$53.16

0.42 (0.80%)

06:32
06/27/17
06/27
06:32
06/27/17
06:32
Downgrade
Helmerich & Payne rating change  »

Helmerich & Payne…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPN

Superior Energy

$9.78

0.04 (0.41%)

06:31
06/27/17
06/27
06:31
06/27/17
06:31
Downgrade
Superior Energy rating change  »

Superior Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBR

Nabors Industries

$7.93

0.06 (0.76%)

06:31
06/27/17
06/27
06:31
06/27/17
06:31
Downgrade
Nabors Industries rating change  »

Nabors Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHI

Baker Hughes

$53.70

-0.29 (-0.54%)

06:31
06/27/17
06/27
06:31
06/27/17
06:31
Downgrade
Baker Hughes rating change  »

Baker Hughes downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PI

Impinj

$59.37

0.58 (0.99%)

06:31
06/27/17
06/27
06:31
06/27/17
06:31
Downgrade
Impinj rating change  »

Impinj downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GEF

Greif

$55.51

-0.1 (-0.18%)

06:29
06/27/17
06/27
06:29
06/27/17
06:29
Conference/Events
Greif to host investor breakfast day »

Investor Breakfast Day to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

UAA

Under Armour

$21.56

0.36 (1.70%)

, UA

Under Armour

$19.92

0.27 (1.37%)

06:27
06/27/17
06/27
06:27
06/27/17
06:27
Recommendations
Under Armour, Under Armour, Kohl's, Nike, adidas analyst commentary  »

Under Armour still…

UAA

Under Armour

$21.56

0.36 (1.70%)

UA

Under Armour

$19.92

0.27 (1.37%)

KSS

Kohl's

$37.52

0.49 (1.32%)

NKE

Nike

$53.28

0.43 (0.81%)

ADDYY

adidas

$94.38

-0.015 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

LYV

Live Nation

$34.86

0.02 (0.06%)

06:20
06/27/17
06/27
06:20
06/27/17
06:20
Recommendations
Live Nation analyst commentary  »

Live Nation price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLT

Hilton

$65.23

-0.17 (-0.26%)

, CHH

Choice Hotels

$66.25

-0.45 (-0.67%)

06:17
06/27/17
06/27
06:17
06/27/17
06:17
Recommendations
Hilton, Choice Hotels, Hyatt, Marriott analyst commentary  »

Deutsche…

HLT

Hilton

$65.23

-0.17 (-0.26%)

CHH

Choice Hotels

$66.25

-0.45 (-0.67%)

H

Hyatt

$58.09

0.39 (0.68%)

MAR

Marriott

$103.93

-0.13 (-0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

GOOGL

Alphabet Class A

$972.09

-14 (-1.42%)

06:14
06/27/17
06/27
06:14
06/27/17
06:14
Technical Analysis
Technical View: Alphabet Class A falls after EU fine, potential bearish pattern »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSUR

OraSure

$15.72

0.17 (1.09%)

06:10
06/27/17
06/27
06:10
06/27/17
06:10
Hot Stocks
OraSure's HIV self-test supported by Gates Foundation for accelerated adoption »

OraSure entered a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

BABA

Alibaba

$142.73

-0.28 (-0.20%)

06:09
06/27/17
06/27
06:09
06/27/17
06:09
Initiation
Alibaba initiated  »

Alibaba resumed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

RDWR

Radware

$17.94

-0.04 (-0.22%)

06:06
06/27/17
06/27
06:06
06/27/17
06:06
Hot Stocks
Radware granted ISO27017 and ISO27018 cloud services certifications »

Radware has achieved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jul

  • 13

    Jul

GRPN

Groupon

$3.45

-0.02 (-0.58%)

06:06
06/27/17
06/27
06:06
06/27/17
06:06
Recommendations
Groupon analyst commentary  »

Groupon trading well…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDS

GDS Holdings

$8.83

-0.22 (-2.43%)

, BABA

Alibaba

$142.73

-0.28 (-0.20%)

06:05
06/27/17
06/27
06:05
06/27/17
06:05
Hot Stocks
GDS Holdings announces new order from Alibaba for Beijing 3 data center »

GDS Holdings (GDS)…

GDS

GDS Holdings

$8.83

-0.22 (-2.43%)

BABA

Alibaba

$142.73

-0.28 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

MCK

McKesson

$167.61

0.65 (0.39%)

06:04
06/27/17
06/27
06:04
06/27/17
06:04
Conference/Events
McKesson to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 26

    Jul

  • 30

    Jul

INFO

IHS Markit

$46.40

-0.15 (-0.32%)

06:04
06/27/17
06/27
06:04
06/27/17
06:04
Earnings
IHS Markit sees FY17 adjusted EPS $2.02-$2.08, consensus $2.06 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

UCBI

United Community Banks

$26.70

0.22 (0.83%)

, FOFN

Four Oaks Fincorp

$15.18

0.4 (2.71%)

06:03
06/27/17
06/27
06:03
06/27/17
06:03
Hot Stocks
United Community, Banks Four Oaks Fincorp announce merger agreement »

Community Banks (UCBI)…

UCBI

United Community Banks

$26.70

0.22 (0.83%)

FOFN

Four Oaks Fincorp

$15.18

0.4 (2.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.